BOSTON - Seaport Therapeutics, a clinical-stage biopharmaceutical company, has published new research demonstrating significant advancements in drug delivery through the lymphatic system using its ...

Mycophenolic acid (MPA), an existing IMPDH inhibitor, emerged as a potential therapeutic agent. However, its limited ability to cross the blood-brain barrier necessitated further innovation.

Summary: EC mycophenolate sodium is the EC salt form of mycophenolic acid (MPA), the active component of the pro-drug, mycophenolate mofetil. EC mycophenolate sodium was developed to reduce the ...

The area under the curve plasma concentrations of mycophenolic acid seemed to be suboptimal among ... plasma levels of MPA were measured to assess differences between acute and chronic GVHD ...

PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform ...